CEO Robert Blum was paid $11,881,456 in fiscal year 2025, ↓ down 17.3% from fiscal year 2024, the 53rd percentile of its disclosed peer group (SEC filing 0001140361-26-015364 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$11,881,456 ↓ Robert Blum total, FY2025 | 53rd CEO pay percentile vs peers | 1:1 CEO-to-median pay ratio | 97.18% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CYTK's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Blum | $853,069 | $0 | $5,150,019 | $5,095,918 | $772,715 | $0 | $9,735 | $11,881,456 |
| President and Chief Executive Officer | ||||||||
| Jeffrey Hessekiel | 85,250 | 200,000 | 5,800,013 | 0 | 0 | 0 | 954 | 6,086,217 |
| Executive Vice President, Chief Legal and Administrative Officer | ||||||||
| Fady Malik | 629,781 | 0 | 1,750,002 | 1,731,616 | 335,144 | 0 | 20,523 | 4,467,066 |
| Executive Vice President, Research and Development | ||||||||
| Andrew Callos | 581,678 | 0 | 1,449,995 | 1,434,764 | 302,960 | 0 | 18,247 | 3,787,644 |
| Executive Vice President, Chief Commercial Officer | ||||||||
| Sung Lee | 572,918 | 0 | 1,449,995 | 1,434,764 | 295,608 | 0 | 17,522 | 3,770,807 |
| Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Blum | $11,881,456 | $14,368,343 | $8,751,057 | ↓ −2,486,887 |
| Jeffrey Hessekiel | 6,086,217 | — | — | — |
| Fady Malik | 4,467,066 | 5,371,389 | 4,439,665 | ↓ −904,323 |
| Andrew Callos | 3,787,644 | 4,389,027 | 3,198,488 | ↓ −601,383 |
| Sung Lee | 3,770,807 | 5,918,931 | — | ↓ −2,148,124 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read CYTOKINETICS INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CYTK reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the CYTOKINETICS INC Peer Teardown Report
$11,881,456 Robert Blum total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 13, 2026 · Source: 0001140361-26-015364 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for CYTK
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order CYTK
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses CYTK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CYTK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the CYTOKINETICS INC Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Jeffrey Hessekiel | General Counsel | $6,086,217 |
| Andrew Callos | CCO | $3,787,644 |
| Robert Blum | CEO | $11,881,456 |
| Sung Lee | CFO | $3,770,807 |
| Fady Malik | EVP | $4,467,066 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| B. Lynne Parshall | Independent Director | $540,000 |
| Edward M. Kaye | Independent Director | $478,815 |
| Fiona Bhanji | Independent Director | $520,750 |
| John T. Henderson | Independent Director | $480,294 |
| Nancy J. Wysenski | Independent Director | $501,338 |
| Robert A. Harrington | Independent Director | $453,315 |
| Robert E. Daly | Independent Director | $721,563 |
| Robert E. Landry | Independent Director | $1,194,688 |
| Wendell Wierenga | Independent Director | $504,588 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Fady Malik | EVP Research & Development | 2026-04-21 | D | 3,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-04-21 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-04-21 | D | 3,500 | 66 | 229,915 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-04-29 | D | 7,500 | 60 | 447,150 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-04-30 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-04-30 | A | 15,000 | 23 | 348,900 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-04-30 | D | 15,000 | 63 | 948,900 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-01 | D | 15,857 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-01 | A | 15,857 | 38 | 596,699 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-01 | D | 15,857 | 65 | 1,030,705 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-05 | D | 11,333 | 77 | 875,474 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-05 | D | 4,032 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-05 | D | 4,032 | 75 | 302,400 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-05 | D | 3,500 | 77 | 270,795 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-05 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-05-05 | D | 23,906 | 77 | 1,837,654 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-05 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-05 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-05 | D | 11,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-05 | A | 11,333 | 39 | 443,460 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-05 | D | 20,000 | 76 | 1,519,400 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-05 | A | 4,032 | 12 | 49,997 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-05 | A | 20,000 | 8 | 152,200 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-05-14 | D | 7,500 | 78 | 584,400 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-19 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-19 | D | 3,500 | 76 | 264,915 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-19 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Nancy J. Wysenski | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy J. Wysenski | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Harrington | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Daly | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Fiona Bhanji | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Harrington | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-05-27 | D | 7,500 | 77 | 579,075 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert E. Daly | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fiona Bhanji | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-06-01 | D | 15,000 | 74 | 1,111,200 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-06-01 | A | 15,000 | 23 | 348,900 | Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-06-01 | D | 2,933 | 76 | 223,172 | Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-06-01 | D | 5,000 | 74 | 370,400 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-06-01 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-09 | D | 3,500 | 68 | 237,930 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-09 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-09 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-06-15 | D | 7,500 | 70 | 528,450 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-23 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-23 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-23 | D | 3,500 | 80 | 278,285 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-24 | — | 3,236 | — | — | 1 insider, 4 accrual rows | ||
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 2,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 9,307 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 23,370 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 23,370 | 49 | 1,133,679 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 1,113 | 49 | 53,992 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 2,817 | 44 | 124,962 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 38,730 | 82 | 3,187,479 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 822 | 44 | 36,464 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 188 | 44 | 8,340 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 1,113 | 49 | 53,992 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 9,307 | 44 | 412,859 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-29 | — | 3,134 | — | — | 1 insider, 5 accrual rows | ||
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 3,134 | 85 | 266,390 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 188 | 44 | 8,340 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 1,113 | 49 | 53,992 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 822 | 44 | 36,464 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 188 | 44 | 8,340 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 823 | 44 | 36,508 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-07-01 | A | 1,112 | 49 | 53,943 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-01 | — | 1,112 | — | — | 1 insider, 1 accrual row | ||
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-01 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-01 | D | 15,000 | 86 | 1,287,000 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-01 | A | 15,000 | 23 | 348,900 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-01 | D | 7,500 | 85 | 636,900 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-07-01 | D | 1,112 | 88 | 97,622 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-07 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-07 | D | 3,500 | 87 | 303,170 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-07 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | D | 7,490 | 82 | 614,330 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | D | 10 | 82 | 820 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | D | 7,490 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | A | 7,490 | 11 | 79,394 | Common | Form 4 ↗ |
| Robert E. Daly | Director | 2026-07-15 | A | 151 | 83 | 12,476 | Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-07-15 | A | 151 | 83 | 12,476 | Common | Form 4 ↗ |
| Nancy J. Wysenski | Director | 2026-07-15 | A | 75 | 83 | 6,197 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-07-15 | A | 75 | 83 | 6,197 | Common | Form 4 ↗ |
| Robert A. Harrington | Director | 2026-07-15 | A | 151 | 83 | 12,476 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-07-15 | A | 272 | 83 | 22,473 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-21 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-21 | D | 3,500 | 81 | 282,065 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-21 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-27 | D | 7,500 | 81 | 606,525 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-27 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-27 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-30 | D | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-30 | D | 14,000 | 80 | 1,118,320 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-30 | A | 14,000 | 23 | 325,640 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-10 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-10 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-10 | D | 7,500 | 77 | 575,700 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-08-18 | D | 3,500 | 76 | 265,370 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-08-18 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-08-18 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-31 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-31 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-08-31 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-08-31 | D | 10,000 | 70 | 702,400 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-08-31 | A | 10,000 | 23 | 232,600 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-31 | D | 7,500 | 70 | 526,800 | Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-09-01 | D | 5,000 | 71 | 357,400 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-08 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-08 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-08 | D | 3,500 | 75 | 264,110 | Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-09-11 | D | 1,000 | 75 | 74,660 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 1,350 | 0 | 0 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 97,926 | 0 | 0 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 7,500 | 73 | 550,800 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | A | 97,926 | 0 | 0 | Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-09-15 | D | 1,000 | 72 | 72,130 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-15 | D | 97,926 | 69 | 6,789,210 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-22 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-22 | D | 3,500 | 68 | 239,015 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-22 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-28 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-28 | D | 7,500 | 65 | 490,950 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-28 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-10-06 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-10-06 | D | 3,500 | 61 | 214,830 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-10-06 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-10-12 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-10-12 | D | 7,500 | 63 | 471,600 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-10-12 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Fady Malik | EVP Research & Development | 2026-04-21 | D | 3,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-04-21 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-04-21 | D | 3,500 | 66 | 229,915 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-04-29 | D | 7,500 | 60 | 447,150 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-04-30 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-04-30 | A | 15,000 | 23 | 348,900 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-04-30 | D | 15,000 | 63 | 948,900 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-01 | D | 15,857 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-01 | A | 15,857 | 38 | 596,699 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-01 | D | 15,857 | 65 | 1,030,705 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-05 | D | 11,333 | 77 | 875,474 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-05 | D | 4,032 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-05 | D | 4,032 | 75 | 302,400 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-05 | D | 3,500 | 77 | 270,795 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-05 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-05-05 | D | 23,906 | 77 | 1,837,654 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-05 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-05 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-05 | D | 11,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-05-05 | A | 11,333 | 39 | 443,460 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-05 | D | 20,000 | 76 | 1,519,400 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-05 | A | 4,032 | 12 | 49,997 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-05 | A | 20,000 | 8 | 152,200 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-05-14 | D | 7,500 | 78 | 584,400 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-19 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-19 | D | 3,500 | 76 | 264,915 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-05-19 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Nancy J. Wysenski | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy J. Wysenski | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Harrington | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Daly | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Fiona Bhanji | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert A. Harrington | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-05-27 | D | 7,500 | 77 | 579,075 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-05-27 | A | 2,851 | 0 | 0 | Common | Form 4 ↗ |
| Robert E. Daly | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fiona Bhanji | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-05-27 | A | 4,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-06-01 | D | 15,000 | 74 | 1,111,200 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-06-01 | A | 15,000 | 23 | 348,900 | Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-06-01 | D | 2,933 | 76 | 223,172 | Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-06-01 | D | 5,000 | 74 | 370,400 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-06-01 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-09 | D | 3,500 | 68 | 237,930 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-09 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-09 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-06-15 | D | 7,500 | 70 | 528,450 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-23 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-23 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-06-23 | D | 3,500 | 80 | 278,285 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 1,113 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 822 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 1,113 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 2,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 9,307 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 23,370 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 23,370 | 49 | 1,133,679 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 1,113 | 49 | 53,992 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 2,817 | 44 | 124,962 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 188 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | D | 38,730 | 82 | 3,187,479 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 822 | 44 | 36,464 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 188 | 44 | 8,340 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 1,113 | 49 | 53,992 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-24 | A | 9,307 | 44 | 412,859 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 188 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 3,134 | 85 | 266,390 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 188 | 44 | 8,340 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 1,113 | 49 | 53,992 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 822 | 44 | 36,464 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 1,113 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 188 | 44 | 8,340 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 823 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 822 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | D | 188 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-06-29 | A | 823 | 44 | 36,508 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-07-01 | A | 1,112 | 49 | 53,943 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-07-01 | D | 1,112 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-01 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-01 | D | 15,000 | 86 | 1,287,000 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-01 | A | 15,000 | 23 | 348,900 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-01 | D | 7,500 | 85 | 636,900 | Common | Form 4 ↗ |
| Sung Lee | EVP, Chief Financial Officer | 2026-07-01 | D | 1,112 | 88 | 97,622 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-07 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-07 | D | 3,500 | 87 | 303,170 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-07 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | D | 7,490 | 82 | 614,330 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | D | 10 | 82 | 820 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | D | 7,490 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-13 | A | 7,490 | 11 | 79,394 | Common | Form 4 ↗ |
| Robert E. Daly | Director | 2026-07-15 | A | 151 | 83 | 12,476 | Common | Form 4 ↗ |
| Edward M. Kaye | Director | 2026-07-15 | A | 151 | 83 | 12,476 | Common | Form 4 ↗ |
| Nancy J. Wysenski | Director | 2026-07-15 | A | 75 | 83 | 6,197 | Common | Form 4 ↗ |
| Wendell Wierenga | Director | 2026-07-15 | A | 75 | 83 | 6,197 | Common | Form 4 ↗ |
| Robert A. Harrington | Director | 2026-07-15 | A | 151 | 83 | 12,476 | Common | Form 4 ↗ |
| John T. Henderson | Director | 2026-07-15 | A | 272 | 83 | 22,473 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-21 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-21 | D | 3,500 | 81 | 282,065 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-07-21 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-27 | D | 7,500 | 81 | 606,525 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-27 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-07-27 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-30 | D | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-30 | D | 14,000 | 80 | 1,118,320 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-07-30 | A | 14,000 | 23 | 325,640 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-10 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-10 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-10 | D | 7,500 | 77 | 575,700 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-08-18 | D | 3,500 | 76 | 265,370 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-08-18 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-08-18 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-31 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-31 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-08-31 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-08-31 | D | 10,000 | 70 | 702,400 | Common | Form 4 ↗ |
| Andrew Callos | EVP, Chief Commercial Officer | 2026-08-31 | A | 10,000 | 23 | 232,600 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-08-31 | D | 7,500 | 70 | 526,800 | Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-09-01 | D | 5,000 | 71 | 357,400 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-08 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-08 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-08 | D | 3,500 | 75 | 264,110 | Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-09-11 | D | 1,000 | 75 | 74,660 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 1,350 | 0 | 0 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 97,926 | 0 | 0 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 7,500 | 73 | 550,800 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-14 | A | 97,926 | 0 | 0 | Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-09-15 | D | 1,000 | 72 | 72,130 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-15 | D | 97,926 | 69 | 6,789,210 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-22 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-22 | D | 3,500 | 68 | 239,015 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-09-22 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-28 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-28 | D | 7,500 | 65 | 490,950 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-09-28 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-10-06 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-10-06 | D | 3,500 | 61 | 214,830 | Common | Form 4 ↗ |
| Fady Malik | EVP Research & Development | 2026-10-06 | A | 3,500 | 8 | 27,300 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-10-12 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-10-12 | D | 7,500 | 63 | 471,600 | Common | Form 4 ↗ |
| Robert I. Blum | Director | 2026-10-12 | A | 7,500 | 11 | 79,500 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Robert Blum | RSU | 2025-03-15 | — | — | 116,096 | — | $5,150,019 |
| Sung Lee | RSU | 2025-03-15 | — | — | 32,687 | — | 1,449,995 |
| Fady Malik | RSU | 2025-03-15 | — | — | 39,450 | — | 1,750,002 |
| Sung Lee | OPTION | 2025-03-15 | — | — | 48,497 | — | 1,434,764 |
| Robert Blum | OPTION | 2025-03-15 | — | — | 172,249 | — | 5,095,918 |
| Andrew Callos | RSU | 2025-03-15 | — | — | 32,687 | — | 1,449,995 |
| Andrew Callos | OPTION | 2025-03-15 | — | — | 48,497 | — | 1,434,764 |
| Jeffrey Hessekiel | RSU | 2025-11-15 | — | — | 87,297 | — | 5,800,013 |
| Fady Malik | OPTION | 2025-03-15 | — | — | 58,531 | — | 1,731,616 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Robert Blum | $5,150,019 | $0 | $5,095,918 | 0.0% |
| Sung Lee | 1,449,995 | 0 | 1,434,764 | 0.0% |
| Fady Malik | 1,750,002 | 0 | 1,731,616 | 0.0% |
| Andrew Callos | 1,449,995 | 0 | 1,434,764 | 0.0% |
| Jeffrey Hessekiel | 5,800,013 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sung Lee | RSU | 32,687 | — | $2,076,932 |
| Andrew Callos | RSU | 6,000 | — | 381,240 |
| Robert Blum | Option | 39,956 | 63.75 | — |
| Andrew Callos | RSU | 10,164 | — | 645,821 |
| Robert Blum | RSU | 16,500 | — | 1,048,410 |
| Andrew Callos | RSU | 1,589 | — | 100,933 |
| Robert Blum | Option | 51,563 | 39.13 | — |
| Sung Lee | RSU | 20,810 | — | 1,322,267 |
| Robert Blum | RSU | 5,765 | — | 366,308 |
| Sung Lee | Option | 32,273 | 48.51 | — |
| Robert Blum | RSU | 116,096 | — | 7,376,740 |
| Sung Lee | RSU | 2,152 | — | 136,706 |
| Andrew Callos | Option | 15,625 | 39.13 | — |
| Robert Blum | RSU | 36,894 | — | 2,344,245 |
| Robert Blum | Option | 11,250 | 37.63 | — |
| Andrew Callos | Option | 39,404 | 44.36 | — |
| Andrew Callos | Option | 11,009 | 63.75 | — |
| Andrew Callos | Option | 2,813 | 37.63 | — |
| Andrew Callos | RSU | 32,687 | — | 2,076,932 |
| Sung Lee | Option | 39,404 | 44.36 | — |
| Jeffrey Hessekiel | RSU | 87,297 | — | 5,546,851 |
| Robert Blum | Option | 139,953 | 44.36 | — |
The Compensation Committee aims to provide target total cash and long-term equity compensation at or around the median of the compensation paid to similarly situated executives employed by the Peer Companies for target level performance, with compensation above this level possible for exceptional performance.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Human Capital Solutions |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-27 | 104,005,531 | 3,018,095 | 844,592 | 97.18% | Passed |
| 2025 | 2025-05-14 | 96,760,272 | 4,607,831 | 250,937 | 95.45% | Passed |
| 2024 | 2024-05-15 | 85,814,395 | 2,927,007 | 790,693 | 96.7% | Passed |
| 2023 | 2023-05-10 | 83,090,317 | 3,278,668 | 147,612 | 96.04% | Passed |
| 2022 | 2022-05-10 | 71,536,813 | 2,039,137 | 446,405 | 96.64% | Passed |
| 2021 | 2021-05-12 | 55,993,232 | 2,372,911 | 285,582 | 95.47% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-27 | 97.18%a |
| 2025 | 2025-05-14 | 95.45%b |
| 2024 | 2024-05-15 | 96.7%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 1 : 1 |
|---|---|
| CEO total compensation | $11,881,456 |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert E. LandryIndependent · Audit | $54,688 | $220,000 | $920,000 | $0 | $0 | $1,194,688 |
| Robert E. DalyIndependent · Compliance · Newly elected | 21,563 | — | 700,000 | 0 | 0 | 721,563 |
| B. Lynne ParshallIndependent · Audit (Chair) · Compliance · Transactions (Chair) | 100,000 | 220,000 | 220,000 | 0 | 0 | 540,000 |
| Fiona BhanjiIndependent · Nominating/Governance · Compliance (Chair) · Transactions | 80,750 | 220,000 | 220,000 | 0 | 0 | 520,750 |
| Wendell WierengaIndependent · Compensation and Talent · Nominating/Governance · Science and Technology (Chair) | 64,588 | 220,000 | 220,000 | 0 | 0 | 504,588 |
| Nancy J. WysenskiIndependent · Compensation and Talent (Chair) · Compliance · Transactions | 61,338 | 220,000 | 220,000 | 0 | 0 | 501,338 |
| John T. HendersonIndependent · Audit · Nominating/Governance (Chair) · Science and Technology · Transactions | 40,294 | 220,000 | 220,000 | 0 | 0 | 480,294 |
| Edward M. KayeIndependent · Audit · Compensation and Talent · Science and Technology · Transactions | 38,815 | 220,000 | 220,000 | 0 | 0 | 478,815 |
| Robert A. HarringtonIndependent · Nominating/Governance · Science and Technology | 13,315 | 220,000 | 220,000 | 0 | 0 | 453,315 |
| Robert I. BlumEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $440,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer (committee retainers excluded) for non-executive directors |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $475,351 |
| Equity awards (grant-date value) | $1,760,000 |
| All other compensation | $0 |
| Total cost of the board | $2,235,351 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies CYTOKINETICS INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including CYTOKINETICS INC.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | $1,000,000 | $19,350,145 | $1,650,014 | $1,147,500 | $23,166,223 |
| 2 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 5 | INSMED Inc. | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 6 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 7 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 8 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 9 | ImmunityBio, Inc. | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 10 | CYTOKINETICS INC | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 11 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 12 | Ultragenyx Pharmaceuticals Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 13 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 14 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 15 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 16 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 17 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 18 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 19 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 20 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| — | Ascendis Pharma A/S | — | — | — | — | — | — | not in coverage universe |
| — | Legend Biotech Corp | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| CYTOKINETICS INC | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arrowhead Pharmaceuticals, Inc. | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Ascendis Pharma A/S | not disclosed | not disclosed | not disclosed | not disclosed |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| ImmunityBio, Inc. | not disclosed | Options 75 · RSU 25 | not disclosed | Mercer |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| INSMED Inc. | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Legend Biotech Corp | not disclosed | not disclosed | not disclosed | not disclosed |
| Madrigal Pharmaceuticals, Inc. | 195% | PSU 33 · RSU 33 · Options 33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceuticals Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Blum | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Executive Summary Compensation Table for 2025”. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103 |
| 2 | Section 01, Jeffrey Hessekiel | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Executive Summary Compensation Table for 2025”. As printed: 6,086,217. Filing ↗machine: r8 · c25 · span 806202–806211 |
| 3 | Section 01, Fady Malik | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Executive Summary Compensation Table for 2025”. As printed: 4,467,066. Filing ↗machine: r11 · c25 · span 820906–820915 |
| 4 | Section 01, Andrew Callos | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Executive Summary Compensation Table for 2025”. As printed: 3,787,644. Filing ↗machine: r5 · c25 · span 791561–791570 |
| 5 | Section 01, Sung Lee | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Executive Summary Compensation Table for 2025”. As printed: 3,770,807. Filing ↗machine: r9 · c25 · span 811013–811022 |
| 6 | Section 03, Robert Blum RSU | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r4 · c16 · span 864649–864656 |
| 7 | Section 03, Sung Lee RSU | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r12 · c16 · span 904946–904952 |
| 8 | Section 03, Fady Malik RSU | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r15 · c16 · span 919905–919911 |
| 9 | Section 03, Sung Lee OPTION | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r13 · c19 · span 911039–911045 |
| 10 | Section 03, Robert Blum OPTION | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r5 · c19 · span 870700–870707 |
| 11 | Section 03, Andrew Callos RSU | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r7 · c16 · span 879676–879682 |
| 12 | Section 03, Andrew Callos OPTION | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r8 · c19 · span 884959–884965 |
| 13 | Section 03, Jeffrey Hessekiel RSU | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r10 · c16 · span 894294–894300 |
| 14 | Section 03, Fady Malik OPTION | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r16 · c19 · span 924340–924346 |
| 15 | Section 07, pay ratio | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “CEO Pay Ratio”. As printed: 1 : 1. Filing ↗machine: t249 · r1 · c4 · span 1262492–1262503 |
| 16 | Section 08, Robert E. Landry | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 1,194,688. Filing ↗machine: t283 · r7 · c13 · span 1478510–1478672 |
| 17 | Section 08, Robert E. Daly | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 721,563. Filing ↗machine: t283 · r4 · c13 · span 1470996–1471199 |
| 18 | Section 08, B. Lynne Parshall | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 540,000. Filing ↗machine: t283 · r8 · c13 · span 1481167–1481370 |
| 19 | Section 08, Fiona Bhanji | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 520,750. Filing ↗machine: t283 · r3 · c13 · span 1468217–1468420 |
| 20 | Section 08, Wendell Wierenga | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 504,588. Filing ↗machine: t283 · r9 · c13 · span 1483556–1483759 |
| 21 | Section 08, Nancy J. Wysenski | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 501,338. Filing ↗machine: t283 · r10 · c13 · span 1486176–1486378 |
| 22 | Section 08, John T. Henderson | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 480,294. Filing ↗machine: t283 · r2 · c13 · span 1465830–1466033 |
| 23 | Section 08, Edward M. Kaye | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 478,815. Filing ↗machine: t283 · r6 · c13 · span 1476123–1476326 |
| 24 | Section 08, Robert A. Harrington | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 453,315. Filing ↗machine: t283 · r5 · c13 · span 1473387–1473590 |
| 25 | Section 08, Robert I. Blum | DEF 14A | 2026-04-17 | 0001140361-26-015364 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, Fady Malik 2026-04-21 | Form 4 | 2026-04-21 | 0001061983-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Fady Malik 2026-04-21 | Form 4 | 2026-04-21 | 0001061983-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Fady Malik 2026-04-21 | Form 4 | 2026-04-21 | 0001061983-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Robert I. Blum 2026-04-29 | Form 4 | 2026-04-29 | 0001061983-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Andrew Callos 2026-04-30 | Form 4 | 2026-04-30 | 0001061983-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Andrew Callos 2026-04-30 | Form 4 | 2026-04-30 | 0001061983-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Andrew Callos 2026-04-30 | Form 4 | 2026-04-30 | 0001061983-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Andrew Callos 2026-05-01 | Form 4 | 2026-05-04 | 0001061983-26-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Andrew Callos 2026-05-01 | Form 4 | 2026-05-04 | 0001061983-26-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Andrew Callos 2026-05-01 | Form 4 | 2026-05-04 | 0001061983-26-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Andrew Callos 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Wendell Wierenga 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Wendell Wierenga 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Fady Malik 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000051 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Fady Malik 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000051 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Sung Lee 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000049 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, John T. Henderson 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Fady Malik 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000051 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Andrew Callos 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Andrew Callos 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, John T. Henderson 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Wendell Wierenga 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, John T. Henderson 2026-05-05 | Form 4 | 2026-05-05 | 0001061983-26-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Robert I. Blum 2026-05-14 | Form 4 | 2026-05-14 | 0001061983-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Fady Malik 2026-05-19 | Form 4 | 2026-05-20 | 0001061983-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Fady Malik 2026-05-19 | Form 4 | 2026-05-20 | 0001061983-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Fady Malik 2026-05-19 | Form 4 | 2026-05-20 | 0001061983-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Nancy J. Wysenski 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Nancy J. Wysenski 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Wendell Wierenga 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Robert E. Landry 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Edward M. Kaye 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Edward M. Kaye 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Robert A. Harrington 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Robert E. Daly 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Fiona Bhanji 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Robert A. Harrington 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Robert I. Blum 2026-05-27 | Form 4 | 2026-05-28 | 0001061983-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, John T. Henderson 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, John T. Henderson 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Wendell Wierenga 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, B. Lynne Parshall 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000057 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, B. Lynne Parshall 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000057 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Robert E. Daly 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Fiona Bhanji 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Robert E. Landry 2026-05-27 | Form 4 | 2026-05-27 | 0001061983-26-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Andrew Callos 2026-06-01 | Form 4 | 2026-06-01 | 0001061983-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Andrew Callos 2026-06-01 | Form 4 | 2026-06-01 | 0001061983-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Edward M. Kaye 2026-06-01 | Form 4 | 2026-06-01 | 0001061983-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, B. Lynne Parshall 2026-06-01 | Form 4 | 2026-06-01 | 0001061983-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Andrew Callos 2026-06-01 | Form 4 | 2026-06-01 | 0001061983-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Fady Malik 2026-06-09 | Form 4 | 2026-06-09 | 0001061983-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Fady Malik 2026-06-09 | Form 4 | 2026-06-09 | 0001061983-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Fady Malik 2026-06-09 | Form 4 | 2026-06-09 | 0001061983-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Robert I. Blum 2026-06-15 | Form 4 | 2026-06-15 | 0001061983-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Fady Malik 2026-06-23 | Form 4 | 2026-06-23 | 0001061983-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Fady Malik 2026-06-23 | Form 4 | 2026-06-23 | 0001061983-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Fady Malik 2026-06-23 | Form 4 | 2026-06-23 | 0001061983-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Sung Lee 2026-06-24 | Form 4 | 2026-06-29 | 0001061983-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Sung Lee 2026-06-29 | Form 4 | 2026-06-29 | 0001061983-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Sung Lee 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Sung Lee 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Andrew Callos 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Andrew Callos 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Andrew Callos 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Robert I. Blum 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Sung Lee 2026-07-01 | Form 4 | 2026-07-02 | 0001061983-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Fady Malik 2026-07-07 | Form 4 | 2026-07-07 | 0001061983-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Fady Malik 2026-07-07 | Form 4 | 2026-07-07 | 0001061983-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Fady Malik 2026-07-07 | Form 4 | 2026-07-07 | 0001061983-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Robert I. Blum 2026-07-13 | Form 4 | 2026-07-14 | 0001061983-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Robert I. Blum 2026-07-13 | Form 4 | 2026-07-14 | 0001061983-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Robert I. Blum 2026-07-13 | Form 4 | 2026-07-14 | 0001061983-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Robert I. Blum 2026-07-13 | Form 4 | 2026-07-14 | 0001061983-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Robert E. Daly 2026-07-15 | Form 4 | 2026-07-16 | 0001061983-26-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Edward M. Kaye 2026-07-15 | Form 4 | 2026-07-16 | 0001061983-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Nancy J. Wysenski 2026-07-15 | Form 4 | 2026-07-16 | 0001061983-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Wendell Wierenga 2026-07-15 | Form 4 | 2026-07-16 | 0001061983-26-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Robert A. Harrington 2026-07-15 | Form 4 | 2026-07-16 | 0001061983-26-000079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, John T. Henderson 2026-07-15 | Form 4 | 2026-07-16 | 0001061983-26-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Fady Malik 2026-07-21 | Form 4 | 2026-07-23 | 0001061983-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Fady Malik 2026-07-21 | Form 4 | 2026-07-23 | 0001061983-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Fady Malik 2026-07-21 | Form 4 | 2026-07-23 | 0001061983-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Robert I. Blum 2026-07-27 | Form 4 | 2026-07-27 | 0001061983-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Robert I. Blum 2026-07-27 | Form 4 | 2026-07-27 | 0001061983-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Robert I. Blum 2026-07-27 | Form 4 | 2026-07-27 | 0001061983-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Andrew Callos 2026-07-30 | Form 4 | 2026-07-30 | 0001061983-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Andrew Callos 2026-07-30 | Form 4 | 2026-07-30 | 0001061983-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Andrew Callos 2026-07-30 | Form 4 | 2026-07-30 | 0001061983-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Robert I. Blum 2026-08-10 | Form 4 | 2026-08-10 | 0001061983-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Robert I. Blum 2026-08-10 | Form 4 | 2026-08-10 | 0001061983-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Robert I. Blum 2026-08-10 | Form 4 | 2026-08-10 | 0001061983-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Fady Malik 2026-08-18 | Form 4 | 2026-08-18 | 0001061983-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Fady Malik 2026-08-18 | Form 4 | 2026-08-18 | 0001061983-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Fady Malik 2026-08-18 | Form 4 | 2026-08-18 | 0001061983-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Robert I. Blum 2026-08-31 | Form 4 | 2026-08-31 | 0001061983-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Robert I. Blum 2026-08-31 | Form 4 | 2026-08-31 | 0001061983-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Andrew Callos 2026-08-31 | Form 4 | 2026-08-31 | 0001061983-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Andrew Callos 2026-08-31 | Form 4 | 2026-08-31 | 0001061983-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Andrew Callos 2026-08-31 | Form 4 | 2026-08-31 | 0001061983-26-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Robert I. Blum 2026-08-31 | Form 4 | 2026-08-31 | 0001061983-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, B. Lynne Parshall 2026-09-01 | Form 4 | 2026-09-01 | 0001061983-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Fady Malik 2026-09-08 | Form 4 | 2026-09-08 | 0001061983-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Fady Malik 2026-09-08 | Form 4 | 2026-09-08 | 0001061983-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Fady Malik 2026-09-08 | Form 4 | 2026-09-08 | 0001061983-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Robert E. Landry 2026-09-11 | Form 4 | 2026-09-11 | 0001061983-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Robert I. Blum 2026-09-14 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Robert I. Blum 2026-09-14 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Robert I. Blum 2026-09-14 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Robert I. Blum 2026-09-14 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Robert I. Blum 2026-09-14 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Robert I. Blum 2026-09-14 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Robert E. Landry 2026-09-15 | Form 4 | 2026-09-15 | 0001061983-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Robert I. Blum 2026-09-15 | Form 4 | 2026-09-15 | 0001061983-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Fady Malik 2026-09-22 | Form 4 | 2026-09-22 | 0001061983-26-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Fady Malik 2026-09-22 | Form 4 | 2026-09-22 | 0001061983-26-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Fady Malik 2026-09-22 | Form 4 | 2026-09-22 | 0001061983-26-000096 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Robert I. Blum 2026-09-28 | Form 4 | 2026-09-28 | 0001061983-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Robert I. Blum 2026-09-28 | Form 4 | 2026-09-28 | 0001061983-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Robert I. Blum 2026-09-28 | Form 4 | 2026-09-28 | 0001061983-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Fady Malik 2026-10-06 | Form 4 | 2026-10-06 | 0001061983-26-000098 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Fady Malik 2026-10-06 | Form 4 | 2026-10-06 | 0001061983-26-000098 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Fady Malik 2026-10-06 | Form 4 | 2026-10-06 | 0001061983-26-000098 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Robert I. Blum 2026-10-12 | Form 4 | 2026-10-13 | 0001061983-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Robert I. Blum 2026-10-12 | Form 4 | 2026-10-13 | 0001061983-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Robert I. Blum 2026-10-12 | Form 4 | 2026-10-13 | 0001061983-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 06, 2026 vote | Form 8-K | 2026-05-27 | 0001193125-26-241840 | Item 5.07 · say-on-pay result. As reported: 97.18% (votes for as printed: 104,005,531). Filing ↗ |
| 177 | Section 06, 2025 vote | Form 8-K | 2025-05-16 | 0000950170-25-072965 | Item 5.07 · say-on-pay result. As reported: 95.45% (votes for as printed: 96,760,272). Filing ↗ |
| 178 | Section 06, 2024 vote | Form 8-K | 2024-05-17 | 0000950170-24-061275 | Item 5.07 · say-on-pay result. As reported: 96.7% (votes for as printed: 85,814,395). Filing ↗ |
| 179 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 180 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 181 | Section 09b board cost (computed) | Computed | — | — | Cash 475,351 + equity 1,760,000 + all other 0 = 2,235,351, summed across the director compensation table rows.machine: formula: Σ = 2,235,351 |
| 182 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 183 | Immunovant, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 184 | Madrigal Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001308179-26-000352 | CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952 |
| 185 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 186 | INSMED Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in INSMED Inc.'s own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 187 | Vaxcyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173672 | CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207 |
| 188 | Blueprint Medicines Corporation, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 189 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 190 | ImmunityBio, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001326110-26-000049 | CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. Filing ↗machine: t62 · r3 · c22 · span 544834–544844 |
| 191 | CYTOKINETICS INC (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001140361-26-015364 | CEO total compensation as printed in CYTOKINETICS INC's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103 |
| 192 | Crinetics Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 193 | Ultragenyx Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceuticals Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 194 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 195 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 196 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 197 | Arrowhead Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 198 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 199 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 200 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 201 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 202 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 203 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 204 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 205 | Section 10a, Crinetics Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 206 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 207 | Section 10a, INSMED Inc. reciprocity | DEF 14A | — | 0001104506-26-000022 | INSMED Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 208 | Section 10a, Madrigal Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001308179-26-000352 | Madrigal Pharmaceuticals, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 209 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 210 | Section 10a, Vaxcyte, Inc. reciprocity | DEF 14A | — | 0001193125-26-173672 | Vaxcyte, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 211 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 212 | Section 10a, Ultragenyx Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 213 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 214 | Section 10a, Blueprint Medicines Corporation reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 215 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 216 | Section 10a, Immunovant, Inc. reciprocity | DEF 14A | — | 0001764013-26-000092 | Immunovant, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 217 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 218 | Section 10a, ImmunityBio, Inc. reciprocity | DEF 14A | — | 0001326110-26-000049 | ImmunityBio, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 219 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
| 220 | Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the CYTOKINETICS INC Executive Compensation Report
$1,500